Visiomed begins clinical evaluation trials
27 June, 2005 by Susan WilliamsonPerth-based biomedical devices developer, Visiomed Group (ASX:VSG) and ophthalmic surgical laser group, CustomVis (AIM:CUS), also based in Perth, have begun a clinical evaluation trial on their ophthalmic imaging system, microEYE.
In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
24 June, 2005 by Ruth BeranThe sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed.
In brief: Pharmaxis, Metabolic, Avantogen, Biotech Capital, Bone Medical, Xceed Biotechnology
23 June, 2005 by Ruth BeranPharmaxis (ASX:PXS) has responded to a request by the ASX to explain why its shares rose from $1.34 on 15 June 2005 to $1.61 on 22 June 2005 by saying that it is unaware of any information that could explain the price change and increase in volume of trading in its shares over that period.
Avastra clinical trial halted
23 June, 2005 by Ruth BeranSydney biomaterials company Avastra (ASX:AVS) has halted its Bioweld human clinical trial due to unexpected results in its long-term animal study, although the company is still unsure what caused the unexpected results.
Low-glycaemic index barley proves healthy alternative
22 June, 2005 by Graeme O'NeillCSIRO Plant Industry released its new low-glyceaemic index barley last week: BARLEYMax, developed from a mutant form of an old 'lab rat' strain of barley called Himalaya.
Bionomics discovers breast cancer diagnostic
22 June, 2005 by Ruth BeranSouth Australian genomics company Bionomics (ASX:BNO) has found that antibodies against it's proprietary cancer drug target BNO69 can be used to distinguish between malignant and benign breast cancers.
Independent clinical study for Solagran's Bioeffective R
21 June, 2005 by Ruth BeranThe Centre for Neuropsychology at Swinburne University of Technology will conduct an independent study, subject to ethical approval, for botanical biotech Solagran (ASX:SLA) to examine the neuro-cognitive, mood and brain EEG effects of Bioeffective R.
Biota rejects offer to drop lawsuit
21 June, 2005 by Graeme O'NeillMelbourne respiratory drug developer Biota Holdings (ASX:BTA) has reportedly rejected a confidential AUD$10 million offer from GlaxoSmithKline (GSK) to drop its lawsuit seeking compensation for loss of royalties from the Australian-developed influenza drug Relenza.
Early warning system developed for avian influenza
21 June, 2005 by Graeme O'NeillVictorian Primary Industry researchers have developed a real-time polymerase chain reaction (PCR) test that will become the basis of an early-warning system for avian influenza.
In brief: Acrux, CyGenics, Iatia, Psivida
20 June, 2005 by Susan WilliamsonAcrux [ASX: ACR] has announced positive results for a Phase 1 proof-of-concept, pharmacokinetic study of its contraceptive spray Nesterone MDTS.
Mayne Group to demerge with new chairmen
17 June, 2005 by Susan WilliamsonAustralian healthcare company, Mayne Group, will proceed with the demerger of its global injectable pharmaceutical business, Mayne Pharma, and its domestic healthcare businesses, Mayne Diagnostic Services, Mayne Pharmacy, and Mayne Consumer Products.
New diagnostic for airborne allergens
17 June, 2005 by Graeme O'NeillA new technique that better identifies asthma and allergy triggers may soon provide some welcome relief to susceptible individuals.
Discovery time recommended in dispute between Ventracor and Heartware
17 June, 2005 by Ruth BeranAn initial recommendation has been made in the patent infringement dispute between Sydney artificial heart firms Ventracor (ASX:VCR) and Heartware (ASX:HTW).
Prana CEO resigns, PBT-2 development to continue
16 June, 2005 by Ruth BeranDr Jonas Alsenas has resigned as CEO and director of Melbourne based Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), with Geoffrey Kempler re-assuming the joint positions of executive chairman and CEO.
In brief: Psiron, pSivida, Meditech Research, Optiscan Imaging
16 June, 2005 by Ruth BeranGreg Williams is Psiron's (ASC:PSX) new chief financial officer, a position he commenced on June 14.
